Featured Research

from universities, journals, and other organizations

Men With Advanced, Incurable Prostate Cancer Can Benefit From Docetaxel

Date:
October 13, 2004
Source:
University Of Toronto
Summary:
An international study led by a Canadian researcher shows that men with advanced, incurable prostate cancer can survive an average of three months longer and face less symptoms when offered a new treatment for prostate cancer.

Toronto (October 6, 2004) – An international study led by a Canadian researcher shows that men with advanced, incurable prostate cancer can survive an average of three months longer and face less symptoms when offered a new treatment for prostate cancer.

Published in tomorrow's issue of The New England Journal of Medicine, the study involved 24 countries and over two years tracked more than 1,000 patients with advanced hormone-refractory prostate cancer. The patients were randomly divided into three groups, with one group receiving the standard chemotherapy (mitoxantrone), while the other two groups received docetaxel either every three weeks or weekly. All three groups received low daily doses of prednisone. Researchers looked at several outcome measures – survival, pain relief, improved quality of life, and the amount of PSA in the patients' blood, which indicates the amount of cancer present in the body. In all these measures, men who received docetaxel administered every three weeks did better than those who received mitoxantrone, and it improved survival by an average of three months. There was no significant difference in survival between those patients receiving docetaxel weekly and those receiving mitoxantrone.

"The new treatment of docetaxel results in many patients feeling better and living a few months longer," said Dr. Ian Tannock, the study's lead author and medical oncologist at Princess Margaret Hospital, senior scientist with Ontario Cancer Institute, and professor with the University of Toronto. "As a result, we are recommending docetaxel every three weeks with daily prednisone as the new standard of treatment for many patients with advanced hormone-refractory prostate cancer."

Prostate cancer is the most common cancer in men. One in eight Canadian men will develop the disease during their lifetime, and most cases are diagnosed in men over the age of 65. Initially, prostate cancer may be treated by surgery, removing the prostate gland, or by radiation therapy. In some cases, the cancer becomes metastatic, spreading to other parts of the body. It is then usually treated by measures that modify the body's hormones, since prostate cancer cells are stimulated to grow by male hormones such as testosterone. However, the cancer may eventually become resistant to hormonal treatment and patients might then benefit from chemotherapy. Docetaxel works by interfering with the cells' ability to divide. Currently used in some breast cancer and lung cancer patients, its side effects include changes in nails, tiredness, tingling and loss of sensation in fingers and toes. Docetaxel has been approved by the U.S. Food and Drug Administration.

###

This research was supported in part by Aventis, the company that manufactures Docetaxel.


Story Source:

The above story is based on materials provided by University Of Toronto. Note: Materials may be edited for content and length.


Cite This Page:

University Of Toronto. "Men With Advanced, Incurable Prostate Cancer Can Benefit From Docetaxel." ScienceDaily. ScienceDaily, 13 October 2004. <www.sciencedaily.com/releases/2004/10/041007085048.htm>.
University Of Toronto. (2004, October 13). Men With Advanced, Incurable Prostate Cancer Can Benefit From Docetaxel. ScienceDaily. Retrieved August 27, 2014 from www.sciencedaily.com/releases/2004/10/041007085048.htm
University Of Toronto. "Men With Advanced, Incurable Prostate Cancer Can Benefit From Docetaxel." ScienceDaily. www.sciencedaily.com/releases/2004/10/041007085048.htm (accessed August 27, 2014).

Share This




More Health & Medicine News

Wednesday, August 27, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Predicting Heart Transplant Rejection With a Blood Test

Predicting Heart Transplant Rejection With a Blood Test

Ivanhoe (Aug. 27, 2014) Now a new approach to rejection of donor organs could change the way doctors predict transplant rejection…without expensive, invasive procedures. Video provided by Ivanhoe
Powered by NewsLook.com
Better Braces That Vibrate

Better Braces That Vibrate

Ivanhoe (Aug. 27, 2014) The length of time you have to keep your braces on could be cut in half thanks to a new device that speeds up the process. Video provided by Ivanhoe
Powered by NewsLook.com
Smartphone App Tracks Your Heart Rate

Smartphone App Tracks Your Heart Rate

Ivanhoe (Aug. 27, 2014) A new app that can track your heart rate 24/7 is available for download in your app store and its convenience could save your life. Video provided by Ivanhoe
Powered by NewsLook.com
Stroke in Young Adults

Stroke in Young Adults

Ivanhoe (Aug. 27, 2014) A stroke can happen at any time and affect anyone regardless of age. This mother chose to give her son independence and continue to live a normal life after he had a stroke at 18 years old. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins